By Fineline Cube 
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has entered into a collaboration with BigHat Biosciences, a biotech company specializing in machine learning (ML)-guided antibody discovery and development. The partnership aims to design and engineer therapeutic antibodies with enhanced functionality, leveraging BigHat’s Milliner platform—a state-of-the-art ML technology suite integrated with a synthetic biology-based high-speed wet lab.
Collaboration Details
In addition to supporting the development of Lilly’s therapeutic programs, BigHat is advancing its own pipeline of next-generation antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) for oncology and immunology applications. Notably, BigHat is preparing to launch a next-generation ADC for gastrointestinal (GI) cancers into clinical trials in 2026. Lilly’s Catalyze360 program will provide strategic support, while BigHat retains full global rights and control over the program.
Equity Investment and Catalyze360 Model
As part of the collaboration, Eli Lilly will make an equity investment in BigHat. This initiative falls under the Lilly Catalyze360 model, a comprehensive approach designed to empower early-stage biotech startups. The model provides startups with access to funding, world-class lab space, and drug development expertise through its three pillars: Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D.-Fineline Info & Tech